For Whom the Door Revolves: Founder and Director of Multiple Biotechnology Companies Became Director of the NCI and Now Nominated to be Acting Commissioner of the FDA

Dr Scott Gottlieb, the first commissioner of the US Food and Drug Administration (FDA) appointed by President Trump, has announced his plans to depart.  At the time of his nomination, Dr Gottlieb's many conflicts of interest were well known (see this NY Times article, for example), as were his exceedingly friendly views of the pharmaceutical/ biotechnology industry (see this long ago post, for

Comments

Post a Comment

Popular posts from this blog

More Health Care Professionals and Trainees Provoked to Resist - Dana-Farber Cancer Institute Protest of Leaders' Acquiescence to Trump's Muslim Travel Ban

The executive order by President Trump that temporarily banned immigration from seven predominantly Muslim countries provoked health care professionals and trainees to challenge another health care leader whom had not been so challenged previously. We recently described how professionals and trainees protested the decision by Cleveland Clinic CEO Toby Cosgrove not to cancel a fund raising event
Read more

Issues at the 18th International Anti-Corruption Conference

Many issues brought up at the 18th International Anti-Corruption Conference (IACC) in Copenhagen, Denmark, were relevant to the problems of conflicts of interest, crime and corruption in health care which we often discuss on Health Care Renewal, and hence bear repeating here. The discussion certainly got at the complexity of fighting corruption, seemingly one of many necessities that has
Read more